Boston Scientific Corporation (BSX) is Upgraded by Argus to Buy

Boston Scientific Corporation (BSX) was Upgraded by Argus to ” Buy”. Earlier the firm had a rating of “Hold ” on the company shares. Argus advised their investors in a research report released on Sep 1, 2016.

Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by Wedbush on Jul 29, 2016 to “Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $23 .Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 28 from a previous price target of $26 .Company shares were Reiterated by The Benchmark Company on Jul 28, 2016 to “Buy”, Firm has raised the Price Target to $ 31 from a previous price target of $25 .

On the company’s financial health, Boston Scientific Corporation reported $0.27 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.27. The company had revenue of $2126.00 million for the quarter, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.

Boston Scientific Corporation opened for trading at $24.03 and hit $24.355 on the upside on Monday, eventually ending the session at $24.3, with a gain of 1.38% or 0.33 points. The heightened volatility saw the trading volume jump to 69,32,297 shares. Company has a market cap of $33,066 M.

In a different news, on Aug 15, 2016, John Bradley Sorenson (SVP, Manuf & Sup Chn) sold 2,500 shares at $23.90 per share price. According to the SEC, on Aug 2, 2016, Michael F Mahoney (President & CEO) sold 44,400 shares at $24.44 per share price. On Aug 2, 2016, Timothy A. Pratt (EVP, GC & Chief Admin Officer) sold 24,000 shares at $24.46 per share price, according to the Form-4 filing with the securities and exchange commission.

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Boston Scientific Corporation

Leave a Reply

Boston Scientific Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Boston Scientific Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.